Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars Adoption In Europe, US: Some Wins, 'Incomplete' Policies

Executive Summary

Industry chieftains and experts, including Sandoz biopharma's global head, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.

You may also be interested in...



AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One

A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.

Educational Barriers Are Still Holding Back Biosimilars

Panellists at a recent webinar hosted by Sandoz on “unlocking the potential of biosimilars” agreed that biologics are increasingly advancing to first-line treatments. However, industry and regulatory leaders cited lack of education as a significant barrier to biosimilars uptake. The experts also offered reasons for the reduced uptake in immunology biosimilars compared to oncology. 

New Medicare Payment Models Should Not Be All About Saving Money, CMMI’s Fowler Says

CMS’s Innovation director Elizabeth Fowler wants to ‘reignite’ momentum behind health care system transformation. What does that mean for biopharma?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel